

BMJ Open

Nocturnal antihypertensive treatment in type 1 diabetes patients with autonomic neuropathy and nondipping of blood pressure during night. Study rationale and design

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006142
Article Type:	Protocol
Date Submitted by the Author:	24-Jul-2014
Complete List of Authors:	Hjortkær, Henrik; Rigshospitalet, Endocrinology Jensen, Tonny; Copenhagen University Hospital, Rigshospitalet, Department of Endocrinology Kofoed, Klaus; Rigshospitalet, Univ. of Copenhagen, Cardiology Mogensen, Ulrik Madsvig; Rigshospitalet, Cardiology Køber, Lars; Rigshospitalet, Cardiology Hilsted, Karen; Rigshospitalet, Endocrinology Nielsen, Helle; Rigshospitalet, Endocrinology Theilade, Karen; Steno Diabetes Center, Hilsted, Jannik; Rigshospitalet, Endocrinology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics
Keywords:	Hypertension < CARDIOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

Nocturnal antihypertensive treatment in type 1 diabetes patients with autonomic neuropathy and nondipping of blood pressure during night. Study rationale and design.

Henrik Hjortkær (1), Tonny Jensen (1), Klaus Kofoed (2), Ulrik Mogensen (2), Lars Køber (2), Karen Lisa Hilsted (1), Helle Corinth (1), Simone Theilade (3), Jannik Hilsted (1)

Department of Endocrinology, Rigshospitalet, University of Copenhagen, Denmark (1)

Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark (2)

Steno Diabetes Center, Gentofte, Denmark (3)

Corresponding author:

Tonny Jensen

Department of endocrinology

Blegdamsvej 9

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

Denmark

e-mail: tonny.jensen@rh.regionh.dk

Telephone: +45 51145569

Fax: +45 35455213

Henrik Hjortkær

Department of endocrinology

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

Denmark

Klaus Kofoed

Department of Cardiology

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

1
2
3
4 **Denmark**

5
6
7 **Ulrik Mogensen**

8 **Department of Cardiology**

9 **Rigshospitalet, University of Copenhagen**

10 **DK-2100 Copenhagen**

11 **Denmark**

12
13
14
15
16
17 **Lars Køber**

18 **Department of Cardiology**

19 **Rigshospitalet, University of Copenhagen**

20 **DK-2100 Copenhagen**

21 **Denmark**

22
23
24
25
26
27 **Karen Lisa Hilsted**

28 **Department of Endocrinology**

29 **Rigshospitalet, University of Copenhagen**

30 **DK-2100 Copenhagen**

31 **Denmark**

32
33
34
35
36
37 **Helle Corinth**

38 **Department of Endocrinology**

39 **Rigshospitalet, University of Copenhagen**

40 **DK-2100 Copenhagen**

41 **Denmark**

42
43
44
45
46
47 **Simone Theilade**

48 **Steno Diabetes Center**

49 **Niels Stensens Vej 2**

50 **DK-2820 Gentofte**

51 **Denmark**

1
2
3
4 **Jannik Hilsted**

5 **Department of Endocrinology**

6 **Rigshospitalet, University of Copenhagen**

7 **DK-2100 Copenhagen**

8 **Denmark**

9
10
11
12
13 **Keywords:**

14 Type 1 Diabetes Mellitus; Blood pressure; Cardiovascular autonomic neuropathy; Blood pressure
15 lowering treatment; Nondipping of blood pressure
16
17
18

19
20 **Word count:**

21 2568
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Cardiac autonomic neuropathy (CAN) and elevated nocturnal blood pressure are independent risk factors for cardiovascular disease in diabetic patients. Previously, associations between CAN, nondipping of nocturnal blood pressure and coronary artery calcification have been demonstrated. The present protocol describes a trial to test the efficacy of bedtime dosing of the angiotensin converting enzyme (ACE) inhibitor Enalapril on night time blood pressure and left ventricular mass in patients with type 1 diabetes.

Materials and methods: In a randomised, double-blind, two-way cross-over study, 24 normoalbuminuric type 1 diabetes patients with CAN will be treated for 12 weeks with either morning or bedtime dosing of 20 mg Enalapril, followed by 12 weeks of switched treatment regimen. During each treatment period, two 24-hour ambulatory blood pressure measurements will be performed and after each treatment period left ventricular mass will be determined by Multisliced Computed Tomography (MSCT). Primary end points will be reduction in blood pressure and reduction in left ventricular mass.

Ethics and dissemination: The study has been approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the Capital Region of Denmark and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospital) will oversee the study. The results of the study will be presented at national and international scientific meetings and publications will be submitted to peer-reviewed journals.

Trial registration: ClinicalTrials.gov

Article summary

Article focus

This study describes a randomised cross-over trial evaluating the efficacy of nocturnal antihypertensive treatment with the ACE-inhibitor enalapril in type 1 diabetic patients with CAN and nondipping of nocturnal blood pressure.

We hypothesise that bedtime dosing of Enalapril will reduce night-time blood pressure and left ventricular mass in type 1 diabetic patients

Key messages

Limited data exist on the clinical effect and safety of nocturnal antihypertensive treatment in patients with type 1 diabetes and CAN.

Current knowledge does not include the effect of bedtime dosing of antihypertensive treatment on left ventricular mass

Strengths and limitations of the study

This will be the first randomised controlled, double-blinded trial examining the effect of night-time antihypertensive treatment in type 1 diabetic patients

The primary end-points, night-time blood pressure and left ventricular mass, are strictly objective

1
2
3
4 The study is powered to conclude on clinical relevant changes in the primary
5
6 endpoints
7
8
9

10
11 The study population of long-term type 1 diabetic patients with autonomic neuropathy
12
13 but normoalbuminuria is highly selected and not representative for the general
14
15 population of type 1 diabetic patients. On the other hand, it enables us to study the
16
17 effect of antihypertensive treatment in patients with CAN without the confounding of
18
19 diabetic nephropathy.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The pathogenesis of hypertension in type 1 diabetic patients comprises substantial vessel wall pathology. A number of observations suggest, however, that also CAN may play a role in the development of hypertension (1).

The normal diurnal variability in blood pressure includes a decline in blood pressure during night and a reduction in heart frequency. The primary cause of reduced heart frequency and the supposed decline in blood pressure is an increased vagal tone during the night (2). CAN affecting vagal nerve function, is a frequent and early complication in type 1 diabetic patients and may play a role in the smaller reduction in heart frequency and thereby the less decline than normal in blood pressure during the night in patients with neuropathy (3).

Associations between CAN and less decline in night blood pressure have been described in a number of observations (1, 4-8) and the condition is encumbered with considerable increased morbidity and mortality (9-14). In a recent study we have shown a relation between CAN, reduced diurnal variability in blood pressure and increased left ventricular mass. Whether this relationship is of importance for the increased morbidity and mortality in patients with CAN is at the moment unclear (15).

Previous studies in patients with essential hypertension have suggested that patients with reduced diurnal variation in blood pressure will reduce the night blood pressure by taking their antihypertensive treatment at bedtime (16). Pharmacological treatment of hypertension can possibly, on its own, improve autonomic dysfunction (17). Heart rate variability was increased in a short study of ACE-inhibitors in type 1 diabetic patients (18). However, no studies on pharmacologically re-establishing the normal diurnal variation in blood pressure in type 1 diabetes have been published despite the request for such a study (19).

1
2
3
4 The first-line choice for treatment of hypertension in type 1 diabetes is ACE-inhibition. The
5 recommended standard dose of Enalapril is 20 mg once daily given in the morning. The maximal
6 antihypertensive effect of the drug is seen after 4-6 hours with diminishing but still present effect on
7 blood pressure for 24 hours. Thus, theoretically, the drug should be ideal for re-establishing the
8 normal diurnal blood pressure variation if given at bedtime.
9

10
11 In the following a protocol for the investigation of the efficacy of nocturnal antihypertensive
12 treatment in patients with type 1 diabetes and isolated autonomic neuropathy including background
13 knowledge, experimental design and planned analyses will be described.
14

15 **Prognosis and present treatment of autonomic diabetic neuropathy**

16
17 CAN is a severe complication to diabetes, and is associated with increased morbidity and mortality
18 (12). CAN rarely exist as an isolated complication to diabetes (10). Furthermore, the mechanisms
19 by which CAN may increase the risk of cardiovascular disease is unknown but factors such as
20 exercise intolerance (19), silent myocardial infarction (20) and arrhythmias (21) have been proposed.
21

22
23 Although specific treatment of the condition does not exist, improvement of glycaemic control can
24 slow the progression of CAN (22), and symptomatic treatment with ACE-inhibitors and beta-
25 blockers is available (23).
26

27
28 Recently, it has been demonstrated that targeting nocturnal hypertension in type 2 diabetic patients
29 by bedtime dosing of antihypertensive medications is able to reduce night time blood pressure
30 significantly (24), and in a large open-labelled study in type 2 diabetes, Hermida et al (25) have
31 demonstrated reduced cardiovascular morbidity and mortality when antihypertensive medication
32 was prescribed at bedtime.
33

34
35 In a previous cross-sectional study of long-term type 1 diabetic patients with isolated CAN we
36 found a close relation between CAN, elevated night time blood pressure and non-dipping of blood
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 pressure during the night. On the assumption that these factors possibly are caused by increased
5
6 sympathetic modulation during night, the present study is designed to elucidate whether night time
7
8 antihypertensive treatment with an ACE-inhibitor, Enalapril, in comparison with morning dosing of
9
10 Enalapril is superior in reducing night-time blood pressure and the frequency of non-dipping of
11
12 blood pressure during night. Moreover, left ventricular mass measured by MSCT scan may
13
14 illustrate if reduced night time blood pressure will be reflected in reduced left ventricular mass.
15
16
17
18
19

20 **Objective**

21
22 The primary objective is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
23
24 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure (MAP),
25
26 systolic blood pressure (SBP), diastolic blood pressure (DBP) and percent dipping in SBP during
27
28 night.
29

30
31 The secondary objective is to evaluate the effect of night or day time dosing of Enalapril on left
32
33 ventricular mass measured by MSCT scan.
34
35
36
37

38 **Methods/design**

39 **Design**

40
41 The study is an investigator-initiated, prospective, randomised, placebo-controlled, double-blind
42
43 cross-over study of 24 weeks duration investigating the effect of Enalapril 20 mg given at bedtime
44
45 or in the morning on diurnal blood pressure. The patients will be randomised to take Enalapril 20
46
47 mg in the morning and identical tablets with placebo at bedtime or Enalapril 20 at bedtime and
48
49 placebo in the morning at random order.
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 Recruitment will proceed until 24 subjects have completed 12 weeks of treatment. Participants who
5
6 withdraw, drop out or are excluded will be replaced to ensure 24 fulfilled patients. Participants and
7
8 investigators will be blinded for allocated treatment and kept masked until last patient last visit.
9

10
11 If patients are not treated with antihypertensive medication prior to the screening, 10 mg of
12
13 Enalapril is given in the morning for 4 weeks, assuring the medication is tolerated before
14
15 randomisation to study medication. Patients already treated with ACE-inhibitors or angiotensin 2
16
17 receptor blockers will discontinue this treatment when the study medication is given. All other
18
19 antihypertensive drugs will be prescribed unchanged, and we intend not to intervene with present
20
21 glycaemic control or daily clinical practise.
22
23

24 25 26 **Subjects**

27
28 Patients with long-term type 1 diabetes and CAN defined as two or more abnormal autonomic
29
30 function tests (3): Heart rate variability during deep breathing, Valsalva ratio, lying-to-standing test
31
32 and blood pressure response to standing up, and a reduced diurnal variation in blood pressure, will
33
34 be recruited from the outpatient clinic cohort of type 1 diabetic patients at the Diabetes Unit,
35
36 Rigshospitalet and Steno Diabetes Center.
37

38
39 The inclusion criterion will be type 1 diabetes according to WHO/ADA Criteria, age between 18
40
41 and 75 years, glycosylated HbA1c below 10 % (86 mmol/mol), normal urinary albumin excretion
42
43 and no clinical signs of cardiovascular disease. Exclusion criterias are urinary albumin excretion
44
45 rate above 30 mg/24hour, serum creatinin above 120 μ mol/l, renal artery stenosis or other known
46
47 kidney disease, myocardial infarction or coronary revascularisation, transient ischaemic attack or
48
49 stroke, known side effects to or contraindication for treatment with ACE-inhibitors, or known
50
51 malignant diseases.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Criteria for discontinuation in the study are withdrawal of consent, pregnancy, or noncompliance with the study protocol as judged by the investigators. Inclusion and exclusion criteria are presented in Box 1 and 2.

Box 1 Inclusion criteria

Male or female; aged 18-75 years

Type 1 diabetes according to WHO/ADA criteria

Presence of cardiovascular autonomic neuropathy defined as two or more abnormal autonomic function test

Reduced diurnal variation in blood pressure (<10%)

Glycosylated Hemoglobin A1c < 10% (< 86 mmol/mol)

Normal urinary albumin excretion rate (< 30 mg/24 hour)

No clinical signs of cardiovascular disease

Box 2 Exclusion criteria

Type 2 diabetes

Known side effects such as angioedema to ACE-inhibitor treatment

Cancer or any other clinically significant disorder, which in the investigators opinion could interfere with the results of the trial

Elevated urinary albumin excretion rate (> 30 mg/24 hour)

Serum creatinine above 120 μ mol/l

Known renal artery stenosis or known kidney disease

Previous myocardial infarction or coronary revascularisation, transient ischaemic attack or stroke

Known or suspected abuse of alcohol or narcotics

Experimental design

Suitable participants will receive detailed oral and written information about the study, and sufficient time for reflection will be allowed before written informed consent is obtained. All participants will follow the same study plan with an initial screening visit followed by an intervention period of 24 weeks.

Trial visits and examinations

At the screening visit weight and height are measured without shoes. A 12-lead electrocardiogram is then recorded.

CAN tests. For determination of Heart Rate Variability the patients are asked to breathe deeply at a rate of six breaths per minute while being monitored on a (50 mm/s) 12-lead electrocardiogram. The maximum and minimum heart rates during each breathing cycle are measured, and the mean difference of six cycles will be calculated. Abnormal values are differences below 10 beats/minute. The lying-to-standing heart rate ratio is determined after at least 5 minutes rest in the supine position and the maximal-to-minimal heart rate ratio is calculated from the R-R interval measured after the 30th beat after standing up, to the R-R interval measured after the 15th beat after standing up. An abnormal value will be a ratio below or equal to one. The Valsalva test consist of forced exhalation into a mouthpiece with a pressure of 40 mm Hg for 15 seconds, and the ratio of the maximum to the minimum R-R interval during the test is calculated. The test is performed three times, and the mean value of the ratios is used. Abnormal values will be ratios below or equal to 1.10. Ortostatic hypertension is defined as decrease in systolic blood pressure of 30 mmHg when changing from supine to the upright position.

Ambulatory 24-hour blood pressure recording. Measurements are performed on the non-dominant arm with a properly calibrated Blood Pressure Monitor System 90217 form Space Laboratories

(Washington DC). The systolic blood pressure, diastolic blood pressure and heart rate are measured automatically every 20 min during daytime (between 0600 and 2200 h) and once every hour during nighttime (between 2200 and 0600 h) for 24 consecutive hours. Blood pressure will be validated within 2 days after delivery and measurements are not considered valid if > 30% of the measurements are missing, or if not at least 20 measurements during daytime and at least 7 measurements during nighttime are obtained. In these cases, the measurements will be repeated immediately to ensure a sufficient number of measurements.

Blood samples will be collected, medical history will be recorded and a full physical examination will be performed. All female participants of childbearing potential will be tested for pregnancy, and assurance will be obtained of adequate use of anti-contraceptive methods throughout the study period.

During the intervention period, all participants will attend 7 planned visits: randomisation (week 0), week 6, week 11, week 12, week 18, week 23 and week 24. At week 0, 11 and 23 blood samples will be collected and trial medication will be dispensed. At visits 1-7 used packaging will be collected to estimate compliance, adverse events will be assessed and glycaemic control will be evaluated.

At week 6, 11, 18 and 23 ambulatory 24-hour blood pressure recordings will be performed.

At the end of the two study periods (at week 12 and 24), (MSCT) (Toshiba Aquillon One 320 volume) is performed measuring ventricular mass and volume, coronary artery stenosis and coronary calcium score.

Intervention

Trial medication will be initiated on the randomisation day in a dosage of Enalapril 20 mg given in the morning or at bedtime and identical placebo tablets given in the morning and at bedtime. In

1
2
3
4 patients not taking ACE-inhibitors before entrance into the study, a dose of Enalapril 10 mg in the
5
6 morning is given for 4 weeks to ensure tolerability of the drug. Thereafter, these patients are
7
8 randomised to Enalapril 20 mg given in the morning or at bedtime. Patients already in treatment
9
10 with ACE-inhibitors or ATII-blockers will discontinue this treatment when entering the study. All
11
12 other antihypertensive medication will be prescribed unchanged
13
14

15 16 17 18 **End-point measures** 19

20 The primary endpoint is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
21
22 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure, systolic
23
24 blood pressure, diastolic blood pressure and percent dipping in MAP during night. The calculations
25
26 will be based on both 24-hour blood pressure readings in each treatment period.
27

28
29 Secondary endpoint is left ventricular volume and left ventricular mass measured by MSCT at the
30
31 end of each treatment period.
32
33

34 35 36 **Power calculation and statistics** 37

38 The crossover design makes it possible to compare the two treatment modalities within the same
39
40 person thereby minimising between-patient variation.
41

42
43 Setting power to 80%, a test level of 5% and a standard deviation of 5 mm Hg on blood pressure
44
45 measurements a sample size of 24 patients will be sufficient to detect a difference of 4 mmHg
46
47 between the two treatment modalities.
48

49 The results will be expressed as means and standard deviation when values are normally distributed
50
51 and as medians and interquartile range when the values are not normally distributed. Paired students
52
53 t-tests will be used when the values are skewed; otherwise Wilcoxon's tests for paired differences
54
55 are used. A two-tailed value of $p < 0.05$ will be considered statistically significant.
56
57
58
59
60

Ethics and dissemination

This investigator-initiated, randomised, double-blind trial has the potential to clarify whether it is possible to re-establish the diurnal variation of blood pressure in type 1 diabetic patients with a nondipping pattern of blood pressure during night. A positive outcome for the primary endpoint will also enable us to study the effect on end-organ changes as myocardial hypertrophy. Previous studies have suggested positive effects of bedtime dosing of antihypertensive medications in open, unblinded studies in type 2 diabetic patients, but double-blinded studies have not been performed and no studies at all have been carried out in type 1 diabetics. By studying the selected patients with CAN but without simultaneous diabetic nephropathy it is possible to evaluate the effect of nocturnal antihypertensive treatment in patients with autonomic CAN alone.

A positive outcome for the primary endpoint of the trial may pave the way for dosing antihypertensive medication at bedtime. However, larger trials with longer intervention periods are required to study the effects of such medication on hard clinical outcomes.

The potential side effects and risks will be minimised by close measurements of 24-hour blood pressure and monitoring of kidney function during the study.

The potential disadvantages, including expense of time, potential adverse events and discomfort related to blood pressure measurements and study visits are expected to be overshadowed by the knowledge and possible clinical importance that the trial outcome will produce.

The results of the study will be presented at national and international scientific meetings and publication will be submitted to peer-reviewed journals.

Table 1 Trial visits and examinations

Visit	1	2	3	4	5	6	7
Week	0	6	11	12	18	23	24
Informed consent	X						
Screening and randomisation	X						
Physical examination	X						
Blood samples (a)	X		X			X	
Dispense of trial medication	X		X				
Adverse event assessment		X	X	X	X	X	X
24-h blood pressure recording		X	X		X	X	
Heart-MSCT				X			X

- a) Hba1c, serum creatinine and NT-proBNP
- b) Cardiac Multiple Slice Computed Tomography (MSCT)

Contributorship statement:

TJ substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, drafted the article and has approved this version of the article. HH substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KK, UMM and LK substantial contributed to conception and design of the study, interpretation of data, revised the article and has approved this version of the article. KH contributed to design of the study, acquisition and interpretation of data, revised the article and has approved this version of the article. HN contributed to the design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KT substantial contributed to conception and design of the study, acquisition and analysis of data, revised the article and has approved this version of the article. JH substantial contributed to conception and design of the study, analysis and interpretation of data, revised the article and has approved this version of the article.

Competing interests:

None

Funding

This study was supported by a grant from Arvid Nilssons Foundation.

Data Sharing Statement: No additional data available.

References

- 1) Spallone V, Maiello MR, Cicconetti E, Pannone A, Barini A, Gambardella S, Menzinger G.. Factors determining the 24-h blood pressure profile in normotensive patients with type 1 and type 2 diabetes. *J Hum Hypertens* 2001; 15(4):239-246.
- 2) Taskiran M, Rasmussen V, Rasmussen B, Fritz-Hansen T, Larsson HB, Jensen GB, Hilsted J. Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. *Diabetic Med* 2004;21(6):524-530.
- 3) Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007;115(3):387-397.
- 4) Cardoso CR, Leite NC, Freitas L, Dias SB, Muxfeld ES, Salles GF. Pattern of 24-hour ambulatory blood pressure monitoring in type 2 diabetic patients with cardiovascular dysautonomy. *Hypertens Res* 2008; 31(5):865-872.
- 5) Hornung RS, Mahler RF, Raftery EB. Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function. *Diabetic Med* 1989;6(7):579-585.
- 6) Montegudo PT, Nobrega JC, Cezarini PR, Ferreira SR, Kohlmann O, Ribeiro AB, Zanella M-T. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. *Eur J Endocrinol* 1996;135(6):683-688.
- 7) Spallone V, Bernardi L, Ricordi L, Solda P, Maiello MR, Calciati A, Gombardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympatovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993;42(12):1745-1752.
- 8) Spallone V, Maiello MR, Morganti R, Mandica S, Frajes G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type 1 diabetic patients. *J Hum Hypertens* 2007;21(5):381-386.

- 1
2
3
4 9) Verdeccia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M,
5 Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An
6 independent predictor of prognosis in essential hypertension. *Hypertension* 1994;24(6):793-
7 801.
8
9
10
11
12 10) Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian
13 blood pressure and renal impairment are associated with increased mortality in diabetes
14 mellitus. *Diabetic Med* 2000;17(5):360364.
15
16
17 11) Okhubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubora M,
18 Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamachi S, Imai Y. Prognostic
19 significance of the nocturnal decline in blood pressure in individuals with and without high
20 24-h blood pressure: The Ohasama Study. *J Hypertens* 2002;20(11):2183-2189.
21
22
23 12) Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure
24 variation and all-cause mortality. *Am J Hyertens* 2008;21(1):92-97.
25
26
27 13) Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hand E, McCormack P,
28 Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurements
29 in predicting mortality: The Dublin Outcome Study. *Hypertension* 2005;46(1):156-161.
30
31
32 14) Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklun-Bodegard K, Richart T, Okkubo
33 T, Kuznetsova T, Torp-Pedersn C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E,
34 Stassen JA. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort
35 study. *Lancet* 2007;370(9594)1219-1229.
36
37
38 15) Mogensen UM, Jensen T, Køber L, Kelbæk H, Mathiesen AS, Dixen U, Rossing P, Hilsted
39 J, Kofoed KF. Cardiovascular autonomic neuropathy and subclinical cardiovascular disease
40 in normoalbuminuric type 1 diabetic patients. *Diabetes* 2012;61:1822-1830.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 16) Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure
5 control and reverts the nondipper pattern in patients with resistant hypertension.
6 Hypertension 2008;51(1):69-76.
7
8
9
10 17) Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular
11 autonomic neuropathy and mortality in individuals with diabetes: a metaanalysis. Diabetes
12 Care 2003;26(6):1895-1901.
13
14
15
16
17 18) Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avradimis MJ, Mayroui
18 MC, Karamitsos DT. Effect of chronic quinapril administration on heart rate variability in
19 patients with diabetic autonomic neuropathy. Diabetes Care 1997;20(3):355-361
20
21
22
23 19) Cabezas-Cerrato J, Hermida RC, Cabezas-Agricola JM, Auala DE. Cardiac autonomic
24 neuropathy, estimated cardiovascular risk, and circadian blood pressure pattern in diabetes
25 mellitus. Chronobiol Int 2009;26(5):942-957.
26
27
28
29 20) Roy TM, Peterson, HR, Snider HL, Cyrus J, Broadstone VL, Fell RD, Rothchild AH,
30 Samols E, Pfeifer MA. Autonomic influence on cardiovascular performance in diabetic
31 subjects. Am J Med 1989;87:383-388.
32
33
34
35 21) Airaksinen KEJ. Silent coronary artery disease in diabetes: a feature of autonomic
36 neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-266.
37
38
39 22) Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes
40 Care 2003;26:1553-1579.
41
42
43
44 23) The effect of intensive diabetes therapy on measures of autonomic nervous system function
45 in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423.
46
47
48
49 24) Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE,
50 Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes
51 Association. Diabetes Care 2005;28:956-962.
52
53
54
55
56
57
58
59
60

1
2
3
4 25) Knudsen ST, Ebbelhøj E, Poulsen PL, Hansen KW. Targeting nocturnal hypertension in type
5
6 2 diabetes: bedtime dosing of once-daily antihypertensive drugs reduces night-time BP and
7
8 24-h BP. *Diabetologia* 2013;56(Suppl 1);1208:486.
9

10
11 26) Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood
12
13 pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2
14
15 diabetes. *Diabetes Care* 2011;34:1270-1276.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Nocturnal antihypertensive treatment in type 1 diabetes patients with autonomic neuropathy and nondipping of blood pressure during night: Protocol for a randomised, placebo-controlled, double-blind, two-way cross-over study.

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006142.R1
Article Type:	Protocol
Date Submitted by the Author:	15-Sep-2014
Complete List of Authors:	Hjortkær, Henrik; Rigshospitalet, Endocrinology Jensen, Tonny; Copenhagen University Hospital, Rigshospitalet, Department of Endocrinology Kofoed, Klaus; Rigshospitalet, Univ. of Copenhagen, Cardiology Mogensen, Ulrik Madvig; Rigshospitalet, Cardiology Køber, Lars; Rigshospitalet, Cardiology Hilsted, Karen; Rigshospitalet, Endocrinology Corinth, Helle; Rigshospitalet, Endocrinology Theilade, Karen; Steno Diabetes Center, Hilsted, Jannik; Rigshospitalet, Endocrinology
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Cardiovascular medicine, Pharmacology and therapeutics
Keywords:	Hypertension < CARDIOLOGY, Diabetic neuropathy < DIABETES & ENDOCRINOLOGY, General diabetes < DIABETES & ENDOCRINOLOGY

SCHOLARONE™
Manuscripts

**Nocturnal antihypertensive treatment in type 1 diabetes patients with
autonomic neuropathy and nondipping of blood pressure during night: Protocol
for a randomised, placebo-controlled, double-blind, two-way cross-over study.**

**Henrik Hjortkær (1), Tonny Jensen (1), Klaus Kofoed (2), Ulrik Mogensen (2), Lars Køber
(2), Karen Lisa Hilsted (1), Helle Corinth (1), Simone Theilade (3), Jannik Hilsted (1)**

**Department of Endocrinology, Rigshospitalet, University of Copenhagen, Denmark (1)
Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark (2)
Steno Diabetes Center, Gentofte, Denmark (3)**

Corresponding author:

Tonny Jensen

Department of endocrinology

Blegdamsvej 9

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

Denmark

e-mail: tonny.jensen@rh.regionh.dk

Telephone: +45 51145569

Fax: +45 35455213

Henrik Hjortkær

Department of endocrinology

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

Denmark

Klaus Kofoed

Department of Cardiology

Rigshospitalet, University of Copenhagen

DK-2100 Copenhagen

1
2
3
4 **Denmark**

5
6
7 **Ulrik Mogensen**

8 **Department of Cardiology**

9 **Rigshospitalet, University of Copenhagen**

10 **DK-2100 Copenhagen**

11 **Denmark**

12
13
14
15
16
17 **Lars Køber**

18 **Department of Cardiology**

19 **Rigshospitalet, University of Copenhagen**

20 **DK-2100 Copenhagen**

21 **Denmark**

22
23
24
25
26
27 **Karen Lisa Hilsted**

28 **Department of Endocrinology**

29 **Rigshospitalet, University of Copenhagen**

30 **DK-2100 Copenhagen**

31 **Denmark**

32
33
34
35
36
37 **Helle Corinth**

38 **Department of Endocrinology**

39 **Rigshospitalet, University of Copenhagen**

40 **DK-2100 Copenhagen**

41 **Denmark**

42
43
44
45
46
47 **Simone Theilade**

48 **Steno Diabetes Center**

49 **Niels Stensens Vej 2**

50 **DK-2820 Gentofte**

51 **Denmark**

1
2
3
4 **Jannik Hilsted**

5 **Department of Endocrinology**

6 **Rigshospitalet, University of Copenhagen**

7 **DK-2100 Copenhagen**

8 **Denmark**

9
10
11
12
13 **Keywords:**

14 Type 1 Diabetes Mellitus; Blood pressure; Cardiovascular autonomic neuropathy; Blood pressure
15 lowering treatment; Nondipping of blood pressure
16
17
18

19
20 **Word count:**

21 2568
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Cardiac autonomic neuropathy (CAN) and elevated nocturnal blood pressure are independent risk factors for cardiovascular disease in diabetic patients. Previously, associations between CAN, nondipping of nocturnal blood pressure and coronary artery calcification have been demonstrated. The present protocol describes a trial to test the efficacy of bedtime dosing of the angiotensin converting enzyme (ACE) inhibitor Enalapril on night time blood pressure and left ventricular mass in patients with type 1 diabetes.

Materials and methods: In a randomised, double-blind, two-way cross-over study, 24 normoalbuminuric type 1 diabetes patients with CAN will be treated for 12 weeks with either morning or bedtime dosing of 20 mg Enalapril, followed by 12 weeks of switched treatment regimen. During each treatment period, two 24-hour ambulatory blood pressure measurements will be performed and after each treatment period left ventricular mass will be determined by Multisliced Computed Tomography (MSCT). Primary end points will be reduction in blood pressure and reduction in left ventricular mass.

Ethics and dissemination: The study has been approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the Capital Region of Denmark and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospital) will oversee the study. The results of the study will be presented at national and international scientific meetings and publications will be submitted to peer-reviewed journals.

Trial registration: EudraCT (2012-002136-90)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2014-006142 on 7 October 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Introduction

The pathogenesis of hypertension in type 1 diabetic patients comprises substantial vessel wall pathology. A number of observations suggest, however, that also CAN may play a role in the development of hypertension (1).

The normal diurnal variability in blood pressure includes a decline in blood pressure during night and a reduction in heart frequency. The primary cause of reduced heart frequency and the supposed decline in blood pressure is an increased vagal tone during the night (2). CAN affecting vagal nerve function, is a frequent and early complication in type 1 diabetic patients and may play a role in the smaller reduction in heart frequency and thereby the less decline than normal in blood pressure during the night in patients with neuropathy (3).

Associations between CAN and less decline in night blood pressure have been described in a number of observations (1, 4-8) and the condition is encumbered with considerable increased morbidity and mortality (9-14). In a recent study we have shown a relation between CAN, reduced diurnal variability in blood pressure and increased left ventricular mass. Whether this relationship is of importance for the increased morbidity and mortality in patients with CAN is at the moment unclear (15).

Previous studies in patients with essential hypertension have suggested that patients with reduced diurnal variation in blood pressure will reduce the night blood pressure by taking their antihypertensive treatment at bedtime (16). Pharmacological treatment of hypertension can possibly, on its own, improve autonomic dysfunction (17). Heart rate variability was increased in a short study of ACE-inhibitors in type 1 diabetic patients (18). However, no studies on pharmacologically re-establishing the normal diurnal variation in blood pressure in type 1 diabetes have been published despite the request for such a study (19).

1
2
3
4 The first-line choice for treatment of hypertension in type 1 diabetes is ACE-inhibition. The
5 recommended standard dose of Enalapril is 20 mg once daily given in the morning. The maximal
6 antihypertensive effect of the drug is seen after 4-6 hours with diminishing but still present effect on
7 blood pressure for 24 hours. Thus, theoretically, the drug should be ideal for re-establishing the
8 normal diurnal blood pressure variation if given at bedtime.
9

10
11
12 In the following a protocol for the investigation of the efficacy of nocturnal antihypertensive
13 treatment in patients with type 1 diabetes and isolated autonomic neuropathy including background
14 knowledge, experimental design and planned analyses will be described.
15
16
17
18
19
20
21
22
23

24 **Prognosis and present treatment of autonomic diabetic neuropathy**

25
26 CAN is a severe complication to diabetes, and is associated with increased morbidity and mortality
27 (12). CAN rarely exist as an isolated complication to diabetes (10). Furthermore, the mechanisms
28 by which CAN may increase the risk of cardiovascular disease is unknown but factors such as
29 exercise intolerance (20), silent myocardial infarction (21) and arrhythmias (22) have been proposed.
30
31
32

33
34 Although specific treatment of the condition does not exist, improvement of glycaemic control can
35 slow the progression of CAN (23), and symptomatic treatment with ACE-inhibitors and beta-
36 blockers is available (24).
37
38
39
40
41

42
43 Recently, it has been demonstrated that targeting nocturnal hypertension in type 2 diabetic patients
44 by bedtime dosing of antihypertensive medications is able to reduce night time blood pressure
45 significantly (25), and in a large open-labelled study in type 2 diabetes, Hermida et al (26) have
46 demonstrated reduced cardiovascular morbidity and mortality when antihypertensive medication
47 was prescribed at bedtime.
48
49
50
51
52

53
54 In a previous cross-sectional study of long-term type 1 diabetic patients with isolated CAN we
55 found a close relation between CAN, elevated night time blood pressure and non-dipping of blood
56
57
58
59
60

1
2
3
4 pressure during the night (15). On the assumption that these factors possibly are caused by
5
6 increased sympathetic modulation during night, the present study is designed to elucidate whether
7
8 night time antihypertensive treatment with an ACE-inhibitor, Enalapril, in comparison with
9
10 morning dosing of Enalapril is superior in reducing night-time blood pressure and the frequency of
11
12 non-dipping of blood pressure during night. Moreover, left ventricular mass measured by MSCT
13
14 scan may illustrate if reduced night time blood pressure will be reflected in reduced left ventricular
15
16 mass.
17
18
19
20
21

22 **Objective**

23
24 The primary objective is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
25
26 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure (MAP),
27
28 systolic blood pressure (SBP), diastolic blood pressure (DBP) and percent dipping in SBP during
29
30 night.
31
32

33 The secondary objective is to evaluate the effect of night or day time dosing of Enalapril on left
34
35 ventricular mass measured by MSCT scan.
36
37
38
39

40 **Methods/design**

41 **Design**

42
43 The study is an investigator-initiated, prospective, randomised, placebo-controlled, double-blind
44
45 cross-over study of 24 weeks duration investigating the effect of Enalapril 20 mg given at bedtime
46
47 or in the morning on diurnal blood pressure. The patients will be randomised to take Enalapril 20
48
49 mg in the morning and identical tablets with placebo at bedtime or Enalapril 20 at bedtime and
50
51 placebo in the morning at random order.
52
53
54
55
56
57
58
59
60

1
2
3
4 We have prepared thirty sets of medicine, each containing a box with placebo and a box with active
5
6 medicine. Participants are randomised in blocks of 10 to receive either Enalapril or placebo in the
7
8 first 12 weeks and the opposite in the next 12 weeks. The allocation sequence is generated by the
9
10 chemist at the dispenser and the medicine box-sets are numbered from 101 to 130. The participants
11
12 will be enrolled by the study nurse and the patients are assigned prospectively to treatment from 101
13
14 to 130. Both active medicine and placebo are produced in gelatine coated capsules of similar taste
15
16 and appearance. Patients, study nurse, investigators and laboratory technicians are all blinded to the
17
18 treatment.
19
20

21
22 Recruitment will proceed until 24 subjects have completed 12 weeks of treatment. Participants who
23
24 withdraw, drop out or are excluded will be replaced to ensure 24 fulfilled patients. Participants and
25
26 investigators will be blinded for allocated treatment and kept masked until last patient last visit.
27

28
29 If patients are not treated with antihypertensive medication prior to the screening, 10 mg of
30
31 Enalapril is given in the morning for 4 weeks, assuring the medication is tolerated before
32
33 randomisation to study medication. Patients already treated with ACE-inhibitors or angiotensin 2
34
35 receptor blockers will discontinue this treatment when the study medication is given. All other
36
37 antihypertensive drugs will be prescribed unchanged, and we intend not to intervene with present
38
39 glycaemic control or daily clinical practise.
40
41
42
43

44 **Subjects**

45
46 Patients with long-term type 1 diabetes and CAN defined as two or more abnormal autonomic
47
48 function tests (3): Heart rate variability during deep breathing, Valsalva ratio, lying-to-standing test
49
50 and blood pressure response to standing up, and a reduced diurnal variation in blood pressure, will
51
52 be recruited from the outpatient clinic cohort of type 1 diabetic patients at the Diabetes Unit,
53
54 Rigshospitalet and Steno Diabetes Center.
55
56
57
58
59
60

1
2
3
4 The inclusion criterion will be type 1 diabetes according to WHO/ADA Criteria, age between 18
5 and 75 years, glycosylated HbA1c below 10 % (86 mmol/mol), normal urinary albumin excretion
6 and no clinical signs of cardiovascular disease. Exclusion criterias are urinary albumin excretion
7 rate above 30 mg/24hour, serum creatinin above 120 µmol/l, renal artery stenosis or other known
8 kidney disease, myocardial infarction or coronary revascularisation, transient ischaemic attack or
9 stroke, known side effects to or contraindication for treatment with ACE-inhibitors, or known
10 malignant diseases.

11
12 The criterias for discontinuing the study are unacceptable side effects of the study drug, withdrawal
13 of informed consent or pregnancy. We have not planned to modify the intervention. If side effects
14 appear during the study period the study drug will be discontinued.

15
16 Inclusion and exclusion criteria are presented in Box 1 and 2.

17 18 19 20 21 22 23 24 25 26 27 28 29 30 **Box 1 Inclusion criteria**

31 Male or female; aged 18-75 years

32 Type 1 diabetes according to WHO/ADA criteria

33 Presence of cardiovascular autonomic neuropathy defined as two or more abnormal autonomic
34 function test

35 Reduced diurnal variation in blood pressure (<10%)

36 Glycosylated Hemoglobin A1c < 10% (< 86 mmol/mol)

37 Normal urinary albumin excretion rate (< 30 mg/24 hour)

38 No clinical signs of cardiovascular disease

39 40 41 42 43 44 45 46 47 48 49 50 51 **Box 2 Exclusion criteria**

52 Type 2 diabetes

53 Known side effects such as angioedema to ACE-inhibitor treatment

1
2
3
4 Cancer or any other clinically significant disorder, which in the investigators opinion could interfere
5
6 with the results of the trial
7

8 Elevated urinary albumin excretion rate (> 30 mg/24 hour)
9

10 Serum creatinine above 120 µmol/l
11

12 Known renal artery stenosis or known kidney disease
13

14 Previous myocardial infarction or coronary revascularisation, transient ischaemic attack or stroke
15

16 Known or suspected abuse of alcohol or narcotics
17
18
19
20
21

22 **Experimental design**

23
24 Suitable patients will be approached by telephone contact by one of the investigators (TJ) and by
25 receiving a letter with study information. Interested patients are invited to screening at the hospital.
26
27

28 The patients will again receive detailed oral and written information before consent is obtained.
29

30 Thereafter the screening procedures will be performed All participants will follow the same study
31 plan with an initial screening visit followed by an intervention period of 24 weeks. An outline of the
32 trial visits and examinations is shown in table 1.
33
34
35
36
37
38
39

40 **Trial visits and examinations**

41
42 At the screening visit weight and height are measured without shoes. A 12-lead electrocardiogram
43 is then recorded.
44

45
46 CAN tests. For determination of Heart Rate Variability the patients are asked to breathe deeply at a
47 rate of six breaths per minute while being monitored on a (50 mm/s) 12-lead electrocardiogram. The
48 maximum and minimum heart rates during each breathing cycle are measured, and the mean
49 difference of six cycles will be calculated. Abnormal values are differences below 10 beats/minute
50
51
52
53
54
55
56 .The lying-to-standing heart rate ratio is determined after at least 5 minutes rest in the supine
57
58
59
60

1
2
3
4 position and the maximal-to-minimal heart rate ratio is calculated from the R-R interval measured
5 after the 30th beat after standing up , to the R-R interval measured after the 15th beat after standing
6 up. An abnormal value will be a ratio below or equal to one. The Valsalva test consist of forced
7 up. An abnormal value will be a ratio below or equal to one. The Valsalva test consist of forced
8 exhalation into a mouthpiece with a pressure of 40 mm Hg for 15 seconds, and the ratio of the
9 maximum to the minimum R-R interval during the test is calculated. The test is performed three
10 times, and the mean value of the ratios is used. Abnormal values will be ratios below or equal to
11 1.10. Ortostatic hypertension is defined as decrease in systolic blood pressure of 30 mmHg when
12 changing from supine to the upright position.
13
14

15
16
17
18
19
20
21 Ambulatory 24-hour blood pressure recording. Measurements are performed on the non-dominant
22 arm with a properly calibrated Blood Pressure Monitor System 90217 form Space Laboratories
23 (Washington DC). The systolic blood pressure, diastolic blood pressure and heart rate are
24 measured automatically every 20 min during daytime (between 0600 and 2200 h) and once every
25 hour during nighttime (between 2200 and 0600 h) for 24 consecutive hours. Blood pressure will be
26 validated within 2 days after delivery and measurements are not considered valid if > 30% of the
27 measurements are missing, or if not at least 20 measurements during daytime and at least 7
28 measurements during nighttime are obtained. In these cases, the measurements will be repeated
29 immediately to ensure a sufficient number of measurements.
30
31
32
33
34
35
36
37
38
39
40

41
42 Blood samples will be collected, medical history will be recorded and a full physical examination
43 will be performed. All female participants of childbearing potential will be tested for pregnancy,
44 and assurance will be obtained of adequate use of anti-contraceptive methods throughout the study
45 period.
46
47
48
49

50
51 Data from each patient will be collected and entered consecutively for each patient. Twentyfour
52 hour blood pressure profiles and Multisliced Computed Tomography results are transformed to
53
54
55
56
57
58
59
60

1
2
3
4 paper format and will, together with laboratory data be kept at a laboratory behind locked double
5
6 doors. Data will be destroyed 10 years after the end of the study.
7

8
9 During the intervention period, all participants will attend 7 planned visits: randomisation (week 0),
10 week 6, week 11, week 12, week 18, week 23 and week 24. At week 0, 11 and 23 blood samples
11 will be collected and trial medication will be dispensed. At visits 1-7 used packaging will be
12 collected to estimate compliance, adverse events will be assessed and glycaemic control will be
13 evaluated. To encourage adherence the participants can come to the visits after their own wish
14 (week-day, time of the day etc.). A 24-hour telephone service is available for all patients.
15
16

17
18 At week 6, 11, 18 and 23 ambulatory 24-hour blood pressure recordings will be performed.
19

20
21 At the end of the two study periods (at week 12 and 24), (MSCT) (Toshiba Aquillon One 320
22 volume) is performed measuring ventricular mass and volume, coronary artery stenosis and
23 coronary calcium score.
24
25

26
27 The study will be carried out under the surveillance and guidance of the GCP Unit at Copenhagen
28 University Hospital in compliance with the ICH-GCP guidelines.
29

30
31 The security of the patients will be supervised by blood sample control at the start and the end of
32 the study. We recommend observation and reporting of symptoms and possible side effects in the
33 patients diaries or by use of the 24-hour telephone service to the study staff.
34
35

36 37 38 39 40 41 42 43 44 **Intervention**

45
46 Trial medication will be initiated on the randomisation day in a dosage of Enalapril 20 mg given in
47 the morning or at bedtime and identical placebo tablets given in the morning and at bedtime. In
48 patients not taking ACE-inhibitors before entrance into the study, a dose of Enalapril 10 mg in the
49 morning is given for 4 weeks to ensure tolerability of the drug. Thereafter, these patients are
50 randomised to Enalapril 20 mg given in the morning or at bedtime. Patients already in treatment
51
52
53
54
55
56
57
58
59
60

1
2
3
4 with ACE-inhibitors or ATII-blockers will discontinue this treatment when entering the study. All
5
6 other antihypertensive medication will be prescribed unchanged
7
8
9

10 11 **End-point measures**

12
13 The primary endpoint is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
14 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure, systolic
15 blood pressure, diastolic blood pressure and percent dipping in MAP during night. The calculations
16 will be based on both 24-hour blood pressure readings in each treatment period.
17
18
19

20
21 Secondary endpoint is left ventricular volume and left ventricular mass measured by MSCT at the
22 end of each treatment period.
23
24
25
26
27
28

29 30 **Power calculation and statistics**

31
32 The crossover design makes it possible to compare the two treatment modalities within the same
33 person thereby minimising between-patient variation.
34
35

36
37 Setting power to 80%, a test level of 5% and a standard deviation of 5 mm Hg on blood pressure
38 measurements a sample size of 24 patients will be sufficient to detect a difference of 4 mmHg
39 between the two treatment modalities.
40
41

42
43 The results will be expressed as means and standard deviation when values are normally distributed
44 and as medians and interquartile range when the values are not normally distributed. Paired students
45 t-tests will be used when the values are skewed; otherwise Wilcoxon's tests for paired differences
46 are used. A two-tailed value of $p < 0.05$ will be considered statistically significant.
47
48
49
50
51

52 53 **Ethics and dissemination**

1
2
3
4 This investigator-initiated, randomised, double-blind trial has the potential to clarify whether it is
5 possible to re-establish the diurnal variation of blood pressure in type 1 diabetic patients with a
6 nondipping pattern of blood pressure during night. A positive outcome for the primary endpoint will
7 also enable us to study the effect on end-organ changes as myocardial hypertrophy. Previous studies
8 have suggested positive effects of bedtime dosing of antihypertensive medications in open,
9 unblinded studies in type 2 diabetic patients, but double-blinded studies have not been performed
10 and no studies at all have been carried out in type 1 diabetics. By studying the selected patients with
11 CAN but without simultaneous diabetic nephropathy it is possible to evaluate the effect of nocturnal
12 antihypertensive treatment in patients with autonomic CAN alone.
13
14

15 A positive outcome for the primary endpoint of the trial may pave the way for dosing
16 antihypertensive medication at bedtime. However, larger trials with longer intervention periods are
17 required to study the effects of such medication on hard clinical outcomes.
18
19

20 The potential side effects and risks will be minimised by close measurements of 24-hour blood
21 pressure and monitoring of kidney function during the study.
22
23

24 The potential disadvantages, including expense of time, potential adverse events and discomfort
25 related to blood pressure measurements and study visits are expected to be overshadowed by the
26 knowledge and possible clinical importance that the trial outcome will produce.
27
28

29 The results of the study will be presented at national and international scientific meetings and
30 publication will be submitted to peer-reviewed journals.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1 Trial visits and examinations

Visit	1	2	3	4	5	6	7
Week	0	6	11	12	18	23	24
Informed consent	X						
Screening and randomisation	X						
Physical examination	X						
Blood samples (a)	X		X			X	
Dispense of trial medication	X		X				
Adverse event assessment		X	X	X	X	X	X
24-h blood pressure recording		X	X		X	X	
Heart-MSCT				X			X

a) Hba1c, serum creatinine and NT-proBNP

b) Cardiac Multiple Slice Computed Tomography (MSCT)

Contributorship statement:

TJ substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, drafted the article and has approved this version of the article. HH substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KK, UMM and LK substantial contributed to conception and design of the study, interpretation of data, revised the article and has approved this version of the article. KH contributed to design of the study, acquisition and interpretation of data, revised the article and has approved this version of the article. HN contributed to the design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KT substantial contributed to conception and design of the study, acquisition and analysis of data, revised the article and has approved this version of the article. JH substantial contributed to conception and design of the study, analysis and interpretation of data, revised the article and has approved this version of the article.

Competing interests:

None

Funding

This study was supported by a grant from Arvid Nilssons Foundation.

References

- 1) Spallone V, Maiello MR, Cicconetti E, Pannone A, Barini A, Gambardella S, Menzinger G.. Factors determining the 24-h blood pressure profile in normotensive patients with type 1 and type 2 diabetes. *J Hum Hypertens* 2001; 15(4):239-246.
- 2) Taskiran M, Rasmussen V, Rasmussen B, Fritz-Hansen T, Larsson HB, Jensen GB, Hilsted J. Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. *Diabetic Med* 2004;21(6):524-530.
- 3) Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007;115(3):387-397.
- 4) Cardoso CR, Leite NC, Freitas L, Dias SB, Muxfeld ES, Salles GF. Pattern of 24-hour ambulatory blood pressure monitoring in type 2 diabetic patients with cardiovascular dysautonomy. *Hypertens Res* 2008; 31(5):865-872.
- 5) Hornung RS, Mahler RF, Raftery EB. Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function. *Diabetic Med* 1989;6(7):579-585.
- 6) Montegudo PT, Nobrega JC, Cezarini PR, Ferreira SR, Kohlmann O, Ribeiro AB, Zanella M-T. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. *Eur J Endocrinol* 1996;135(6):683-688.
- 7) Spallone V, Bernardi L, Ricordi L, Solda P, Maiello MR, Calciati A, Gombardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympatovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993;42(12):1745-1752.
- 8) Spallone V, Maiello MR, Morganti R, Mandica S, Frajes G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type 1 diabetic patients. *J Hum Hypertens* 2007;21(5):381-386.

- 1
2
3
4 9) Verdeccia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M,
5 Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An
6 independent predictor of prognosis in essential hypertension. *Hypertension* 1994;24(6):793-
7 801.
8
9
10
11
12 10) Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian
13 blood pressure and renal impairment are associated with increased mortality in diabetes
14 mellitus. *Diabetic Med* 2000;17(5):360364.
15
16
17 11) Okhubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubora M,
18 Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamachi S, Imai Y. Prognostic
19 significance of the nocturnal decline in blood pressure in individuals with and without high
20 24-h blood pressure: The Ohasama Study. *J Hypertens* 2002;20(11):2183-2189.
21
22
23 12) Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure
24 variation and all-cause mortality. *Am J Hyertens* 2008;21(1):92-97.
25
26
27 13) Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hand E, McCormack P,
28 Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurements
29 in predicting mortality: The Dublin Outcome Study. *Hypertension* 2005;46(1):156-161.
30
31
32 14) Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklun-Bodegard K, Richart T, Okkubo
33 T, Kuznetsova T, Torp-Pedersn C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E,
34 Stassen JA. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort
35 study. *Lancet* 2007;370(9594)1219-1229.
36
37
38 15) Mogensen UM, Jensen T, Køber L, Kelbæk H, Mathiesen AS, Dixen U, Rossing P, Hilsted
39 J, Kofoed KF. Cardiovascular autonomic neuropathy and subclinical cardiovascular disease
40 in normoalbuminuric type 1 diabetic patients. *Diabetes* 2012;61:1822-1830.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 16) Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure
5 control and reverts the nondipper pattern in patients with resistant hypertension.
6 Hypertension 2008;51(1):69-76.
7
8
9
10 17) Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular
11 autonomic neuropathy and mortality in individuals with diabetes: a metaanalysis. Diabetes
12 Care 2003;26(6):1895-1901.
13
14
15
16
17 18) Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avradimis MJ, Mayroui
18 MC, Karamitsos DT. Effect of chronic quinapril administration on heart rate variability in
19 patients with diabetic autonomic neuropathy. Diabetes Care 1997;20(3):355-361
20
21
22
23 19) Cabezas-Cerrato J, Hermida RC, Cabezas-Agricola JM, Auala DE. Cardiac autonomic
24 neuropathy, estimated cardiovascular risk, and circadian blood pressure pattern in diabetes
25 mellitus. Chronobiol Int 2009;26(5):942-957.
26
27
28
29 20) Roy TM, Peterson, HR, Snider HL, Cyrus J, Broadstone VL, Fell RD, Rothchild AH,
30 Samols E, Pfeifer MA. Autonomic influence on cardiovascular performance in diabetic
31 subjects. Am J Med 1989;87:383-388.
32
33
34
35 21) Airaksinen KEJ. Silent coronary artery disease in diabetes: a feature of autonomic
36 neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-266.
37
38
39 22) Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes
40 Care 2003;26:1553-1579.
41
42
43
44 23) The effect of intensive diabetes therapy on measures of autonomic nervous system function
45 in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423.
46
47
48
49 24) Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE,
50 Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes
51 Association. Diabetes Care 2005;28:956-962.
52
53
54
55
56
57
58
59
60

- 1
2
3
4 25) Knudsen ST, Ebbelhøj E, Poulsen PL, Hansen KW. Targeting nocturnal hypertension in type
5
6 2 diabetes: bedtime dosing of once-daily antihypertensive drugs reduces night-time BP and
7
8 24-h BP. *Diabetologia* 2013;56(Suppl 1);1208:486.
9
10
11 26) Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood
12
13 pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2
14
15 diabetes. *Diabetes Care* 2011;34:1270-1276.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 **Nocturnal antihypertensive treatment in type 1 diabetes patients with**
9 **autonomic neuropathy and nondipping of blood pressure during night:** **Study**
10 **~~rationale and design.~~ Protocol for a randomised, placebo-controlled, double-**
11 **blind, two-way cross-over study.**
12
13
14

15
16 **Henrik Hjortkær (1), Tonny Jensen (1), Klaus Kofoed (2), Ulrik Mogensen (2), Lars Køber**
17 **(2), Karen Lisa Hilsted (1), Helle Corinth (1), Simone Theilade (3), Jannik Hilsted (1)**
18
19

20 **Department of Endocrinology, Rigshospitalet, University of Copenhagen, Denmark (1)**

21 **Department of Cardiology, Rigshospitalet, University of Copenhagen, Denmark (2)**

22 **Steno Diabetes Center, Gentofte, Denmark (3)**
23
24
25

26 **Corresponding author:**

27 **Tonny Jensen**

28 **Department of endocrinology**

29 **Blegdamsvej 9**

30 **Rigshospitalet, University of Copenhagen**

31 **DK-2100 Copenhagen**

32 **Denmark**

33 **e-mail: tonny.jensen@rh.regionh.dk**

34 **Telephone: +45 51145569**

35 **Fax: +45 35455213**
36
37
38
39
40
41

42 **Henrik Hjortkær**

43 **Department of endocrinology**

44 **Rigshospitalet, University of Copenhagen**

45 **DK-2100 Copenhagen**

46 **Denmark**
47
48
49

50 **Klaus Kofoed**

51 **Department of Cardiology**

52 **Rigshospitalet, University of Copenhagen**
53
54
55
56
57
58
59
60

Formatted: English (U.K.)

Formatted: English (U.K.)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DK-2100 Copenhagen
Denmark

Ulrik Mogensen

Department of Cardiology
Rigshospitalet, University of Copenhagen
DK-2100 Copenhagen
Denmark

Formatted: English (U.K.)

Lars Køber

Department of Cardiology
Rigshospitalet, University of Copenhagen
DK-2100 Copenhagen
Denmark

Karen Lisa Hilsted

Department of Endocrinology
Rigshospitalet, University of Copenhagen
DK-2100 Copenhagen
Denmark

Formatted: English (U.K.)

Helle Corinth

Department of Endocrinology
Rigshospitalet, University of Copenhagen
DK-2100 Copenhagen
Denmark

Simone Theilade

Steno Diabetes Center
Niels Stensens Vej 2

DK-2820 Gentofte
Denmark

Formatted: English (U.K.)

1
2
3
4
5
6
7
8
9 **Jannik Hilsted**

10 **Department of Endocrinology**

11 **Rigshospitalet, University of Copenhagen**

12 **DK-2100 Copenhagen**

13 **Denmark**

14
15
16
17
18 **Keywords:**

19 Type 1 Diabetes Mellitus; Blood pressure; Cardiovascular autonomic neuropathy; Blood pressure
20 lowering treatment; Nondipping of blood pressure
21

22
23 **Word count:**

24 2568
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Introduction: Cardiac autonomic neuropathy (CAN) and elevated nocturnal blood pressure are independent risk factors for cardiovascular disease in diabetic patients. Previously, associations between CAN, nondipping of nocturnal blood pressure and coronary artery calcification have been demonstrated. The present protocol describes a trial to test the efficacy of bedtime dosing of the angiotensin converting enzyme (ACE) inhibitor Enalapril on night time blood pressure and left ventricular mass in patients with type 1 diabetes.

Materials and methods: In a randomised, double-blind, two-way cross-over study, 24 normoalbuminuric type 1 diabetes patients with CAN will be treated for 12 weeks with either morning or bedtime dosing of 20 mg Enalapril, followed by 12 weeks of switched treatment regimen. During each treatment period, two 24-hour ambulatory blood pressure measurements will be performed and after each treatment period left ventricular mass will be determined by Multisliced Computed Tomography (MSCT). Primary end points will be reduction in blood pressure and reduction in left ventricular mass.

Ethics and dissemination: The study has been approved by the Danish Medicines Agency, the Scientific-Ethical Committee of the Capital Region of Denmark and the Danish Data Protection Agency. An external monitoring committee (The Good Clinical Practice Unit at Copenhagen University Hospital) will oversee the study. The results of the study will be presented at national and international scientific meetings and publications will be submitted to peer-reviewed journals.

Trial registration: ClinicalTrials.gov EudraCT (2012-002136-90)

Article summary

Article focus

This study describes a randomised cross-over trial evaluating the efficacy of nocturnal antihypertensive treatment with the ACE-inhibitor enalapril in type 1 diabetic patients with CAN and nondipping of nocturnal blood pressure.

We hypothesise that bedtime dosing of Enalapril will reduce night-time blood pressure and left ventricular mass in type 1 diabetic patients

Key messages

Limited data exist on the clinical effect and safety of nocturnal antihypertensive treatment in patients with type 1 diabetes and CAN.

Current knowledge does not include the effect of bedtime dosing of antihypertensive treatment on left ventricular mass

Strengths and limitations of the study

This will be the first randomised controlled, double-blinded trial examining the effect of night-time antihypertensive treatment in type 1 diabetic patients

The primary end points, night-time blood pressure and left ventricular mass, are strictly objective

The study is powered to conclude on clinical relevant changes in the primary endpoints

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

Formatted: Indent: Left: 0", First line: 0"

Formatted: Indent: Left: 0.91", First line: 0"

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

~~The study population of long term type 1 diabetic patients with autonomic neuropathy but normoalbuminuria is highly selected and not representative for the general population of type 1 diabetic patients. On the other hand, it enables us to study the effect of antihypertensive treatment in patients with CAN without the confounding of diabetic nephropathy.~~

Formatted: Indent: Left: 0", First line: 0"

For peer review only

Introduction

The pathogenesis of hypertension in type 1 diabetic patients comprises substantial vessel wall pathology. A number of observations suggest, however, that also CAN may play a role in the development of hypertension (1).

The normal diurnal variability in blood pressure includes a decline in blood pressure during night and a reduction in heart frequency. The primary cause of reduced heart frequency and the supposed decline in blood pressure is an increased vagal tone during the night (2). CAN affecting vagal nerve function, is a frequent and early complication in type 1 diabetic patients and may play a role in the smaller reduction in heart frequency and thereby the less decline than normal in blood pressure during the night in patients with neuropathy (3).

Associations between CAN and less decline in night blood pressure have been described in a number of observations (1, 4-8) and the condition is encumbered with considerable increased morbidity and mortality (9-14). In a recent study we have shown a relation between CAN, reduced diurnal variability in blood pressure and increased left ventricular mass. Whether this relationship is of importance for the increased morbidity and mortality in patients with CAN is at the moment unclear (15).

Previous studies in patients with essential hypertension have suggested that patients with reduced diurnal variation in blood pressure will reduce the night blood pressure by taking their antihypertensive treatment at bedtime (16). Pharmacological treatment of hypertension can possibly, on its own, improve autonomic dysfunction (17). Heart rate variability was increased in a short study of ACE-inhibitors in type 1 diabetic patients (18). However, no studies on pharmacologically re-establishing the normal diurnal variation in blood pressure in type 1 diabetes have been published despite the request for such a study (19).

1
2
3
4
5
6
7
8 The first-line choice for treatment of hypertension in type 1 diabetes is ACE-inhibition. The
9 recommended standard dose of Enalapril is 20 mg once daily given in the morning. The maximal
10 antihypertensive effect of the drug is seen after 4-6 hours with diminishing but still present effect on
11 blood pressure for 24 hours. Thus, theoretically, the drug should be ideal for re-establishing the
12 normal diurnal blood pressure variation if given at bedtime.
13
14

15
16
17 In the following a protocol for the investigation of the efficacy of nocturnal antihypertensive
18 treatment in patients with type 1 diabetes and isolated autonomic neuropathy including background
19 knowledge, experimental design and planned analyses will be described.
20
21
22
23

24 25 **Prognosis and present treatment of autonomic diabetic neuropathy**

26
27 CAN is a severe complication to diabetes, and is associated with increased morbidity and mortality
28 (12). CAN rarely exist as an isolated complication to diabetes (10). Furthermore, the mechanisms
29 by which CAN may increase the risk of cardiovascular disease is unknown but factors such as
30 exercise intolerance (19), silent myocardial infarction (20) and arrhythmias (21) have been proposed.
31
32

33 Although specific treatment of the condition does not exist, improvement of glycaemic control can
34 slow the progression of CAN (22), and symptomatic treatment with ACE-inhibitors and beta-
35 blockers is available (23).
36
37

38 Recently, it has been demonstrated that targeting nocturnal hypertension in type 2 diabetic patients
39 by bedtime dosing of antihypertensive medications is able to reduce night time blood pressure
40 significantly (24), and in a large open-labelled study in type 2 diabetes, Hermida et al (25) have
41 demonstrated reduced cardiovascular morbidity and mortality when antihypertensive medication
42 was prescribed at bedtime.
43
44

45 In a previous cross-sectional study of long-term type 1 diabetic patients with isolated CAN we
46 found a close relation between CAN, elevated night time blood pressure and non-dipping of blood
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 | pressure during the night (15). On the assumption that these factors possibly are caused by
9
10 increased sympathetic modulation during night, the present study is designed to elucidate whether
11 night time antihypertensive treatment with an ACE-inhibitor, Enalapril, in comparison with
12 morning dosing of Enalapril is superior in reducing night-time blood pressure and the frequency of
13 non-dipping of blood pressure during night. Moreover, left ventricular mass measured by MSCT
14 scan may illustrate if reduced night time blood pressure will be reflected in reduced left ventricular
15 mass.
16
17
18
19
20
21

22 23 **Objective**

24
25 The primary objective is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
26 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure (MAP),
27 systolic blood pressure (SBP), diastolic blood pressure (DBP) and percent dipping in SBP during
28 night.
29
30
31

32
33 The secondary objective is to evaluate the effect of night or day time dosing of Enalapril on left
34 ventricular mass measured by MSCT scan.
35
36
37

38 39 **Methods/design**

40 41 **Design**

42
43 The study is an investigator-initiated, prospective, randomised, placebo-controlled, double-blind
44 cross-over study of 24 weeks duration investigating the effect of Enalapril 20 mg given at bedtime
45 or in the morning on diurnal blood pressure. The patients will be randomised to take Enalapril 20
46 mg in the morning and identical tablets with placebo at bedtime or Enalapril 20 at bedtime and
47 placebo in the morning at random order.
48
49
50
51
52
53
54
55
56
57
58
59
60

We have prepared thirty sets of medicine, each containing a box with placebo and a box with active medicine. Participants are randomised in blocks of 10 to receive either Enalapril or placebo in the first 12 weeks and the opposite in the next 12 weeks. The allocation sequence is generated by the chemist at the dispenser and the medicine box-sets are numbered from 101 to 130. The participants will be enrolled by the study nurse and the patients are assigned prospectively to treatment from 101 to 130. Both active medicine and placebo are produced in gelatine coated capsules of similar taste and appearance. Patients, study nurse, investigators and laboratory technicians are all blinded to the treatment.

Recruitment will proceed until 24 subjects have completed 12 weeks of treatment. Participants who withdraw, drop out or are excluded will be replaced to ensure 24 fulfilled patients. Participants and investigators will be blinded for allocated treatment and kept masked until last patient last visit.

If patients are not treated with antihypertensive medication prior to the screening, 10 mg of Enalapril is given in the morning for 4 weeks, assuring the medication is tolerated before randomisation to study medication. Patients already treated with ACE-inhibitors or angiotensin 2 receptor blockers will discontinue this treatment when the study medication is given. All other antihypertensive drugs will be prescribed unchanged, and we intend not to intervene with present glycaemic control or daily clinical practise.

Subjects

Patients with long-term type 1 diabetes and CAN defined as two or more abnormal autonomic function tests (3): Heart rate variability during deep breathing, Valsalva ratio, lying-to-standing test and blood pressure response to standing up, and a reduced diurnal variation in blood pressure, will be recruited from the outpatient clinic cohort of type 1 diabetic patients at the Diabetes Unit, Rigshospitalet and Steno Diabetes Center.

1
2
3
4
5
6
7
8 The inclusion criterion will be type 1 diabetes according to WHO/ADA Criteria, age between 18
9 and 75 years, glycosylated HbA1c below 10 % (86 mmol/mol), normal urinary albumin excretion
10 and no clinical signs of cardiovascular disease. Exclusion criterias are urinary albumin excretion
11 rate above 30 mg/24hour, serum creatinin above 120 µmol/l, renal artery stenosis or other known
12 kidney desease, myocardial infarction or coronary revascularisation, transient ischaemic attack or
13 stroke, known side effects to or contraindication for treatment with ACE-inhibitors, or known
14 malignant diseases.
15
16

17
18
19
20
21 ~~Criteria for discontinuation in the study are withdrawal of consent, pregnancy, or noncompliance~~
22 ~~with the study protocol as judged by the investigators. The criterias for discontinuing the study are~~
23 ~~unacceptable side effects of the study drug, withdrawal of informed consent or pregnancy. We have~~
24 ~~not planned to modify the intervention. If side effects appear during the study period the study drug~~
25 ~~will be discontinued.~~
26
27
28
29

30 Inclusion and exclusion criteria are presented in Box 1 and 2.
31
32

33 **Box 1 Inclusion criteria**

34 Male or female; aged 18-75 years
35

36 Type 1 diabetes according to WHO/ADA criteria
37

38 Presence of cardiovascular autonomic neuropathy defined as two or more abnormal autonomic
39 function test
40

41 Reduced diurnal variation in blood pressure (<10%)
42

43 Glycosylated Hemoglobin A1c < 10% (< 86 mmol/mol)
44

45 Normal urinary albumin excretion rate (< 30 mg/24 hour)
46

47 No clinical signs of cardiovascular disease
48
49

50 **Box 2 Exclusion criteria**

51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 Type 2 diabetes

9
10 Known side effects such as angioedema to ACE-inhibitor treatment

11 Cancer or any other clinically significant disorder, which in the investigators opinion could interfere
12 with the results of the trial

13
14 Elevated urinary albumin excretion rate (> 30 mg/24 hour)

15
16 Serum creatinine above 120 $\mu\text{mol/l}$

17
18 Known renal artery stenosis or known kidney disease

19
20 Previous myocardial infarction or coronary revascularisation, transient ischaemic attack or stroke

21
22 Known or suspected abuse of alcohol or narcotics
23
24
25
26

27 **Experimental design**

28
29 ~~Suitable participants will receive detailed oral and written information about the study, and~~
30 ~~sufficient time for reflection will be allowed before written informed consent is obtained. Suitable~~
31 ~~patients will be approached by telephone contact by one of the investigators (TJ) and by receiving a~~
32 ~~letter with study information. Interested patients are invited to screening at the hospital. The patients~~
33 ~~will again receive detailed oral and written information before consent is obtained. Thereafter the~~
34 ~~screening procedures will be performed~~ All participants will follow the same study plan with an
35 initial screening visit followed by an intervention period of 24 weeks.
36
37
38
39
40
41
42
43

44 **Trial visits and examinations**

45
46 At the screening visit weight and height are measured without shoes. A 12-lead electrocardiogram
47 is then recorded.

48
49 CAN tests. For determination of Heart Rate Variability the patients are asked to breathe deeply at a
50 rate of six breaths per minute while being monitored on a (50 mm/s) 12-lead electrocardiogram. The
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8 maximum and minimum heart rates during each breathing cycle are measured, and the mean
9 difference of six cycles will be calculated. Abnormal values are differences below 10 beats/minute
10 .The lying-to-standing heart rate ratio is determined after at least 5 minutes rest in the supine
11 position and the maximal-to-minimal heart rate ratio is calculated from the R-R interval measured
12 after the 30th beat after standing up , to the R-R interval measured after the 15th beat after standing
13 up. An abnormal value will be a ratio below or equal to one. The Valsalva test consist of forced
14 exhalation into a mouthpiece with a pressure of 40 mm Hg for 15 seconds, and the ratio of the
15 maximum to the minimum R-R interval during the test is calculated. The test is performed three
16 times, and the mean value of the ratios is used. Abnormal values will be ratios below or equal to
17 1.10. Ortostatic hypertension is defined as decrease in systolic blood pressure of 30 mmHg when
18 changing from supine to the upright position.
19

20
21 Ambulatory 24-hour blood pressure recording. Measurements are performed on the non-dominant
22 arm with a properly calibrated Blood Pressure Monitor System 90217 form Space Laboratories
23 (Washington DC). The systolic blood pressure, diastolic blood pressure and heart rate are
24 measured automatically every 20 min during daytime (between 0600 and 2200 h) and once every
25 hour during nighttime (between 2200 and 0600 h) for 24 consecutive hours. Blood pressure will be
26 validated within 2 days after delivery and measurements are not considered valid if > 30% of the
27 measurements are missing, or if not at least 20 measurements during daytime and at least 7
28 measurements during nighttime are obtained. In these cases, the measurements will be repeated
29 immediately to ensure a sufficient number of measurements.
30

31
32 Blood samples will be collected, medical history will be recorded and a full physical examination
33 will be performed. All female participants of childbearing potential will be tested for pregnancy,
34 and assurance will be obtained of adequate use of anti-contraceptive methods throughout the study
35 period.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data from each patient will be collected and entered consecutively for each patient. Twentyfour hour blood pressure profiles and Multisliced Computed Tomography results are transformed to paper format and will, together with laboratory data be kept at a laboratory behind locked double doors. Data will be destroyed 10 years after the end of the study.

During the intervention period, all participants will attend 7 planned visits: randomisation (week 0), week 6, week 11, week 12, week 18, week 23 and week 24. At week 0, 11 and 23 blood samples will be collected and trial medication will be dispensed. At visits 1-7 used packaging will be collected to estimate compliance, adverse events will be assessed and glycaemic control will be evaluated. To encourage adherence the participants can come to the visits after their own wish (week-day, time of the day etc.). A 24-hour telephone service is available for all patients.

At week 6, 11, 18 and 23 ambulatory 24-hour blood pressure recordings will be performed.

At the end of the two study periods (at week 12 and 24), (MSCT) (Toshiba Aquillon One 320 volume) is performed measuring ventricular mass and volume, coronary artery stenosis and coronary calcium score.

The study will be carried out under the surveillance and guidance of the GCP Unit at Copenhagen University Hospital in compliance with the ICH-GCP guidelines.

The security of the patients will be supervised by blood sample control at the start and the end of the study. We recommend observation and reporting of symptoms and possible side effects in the patients diaries or by use of the 24-hour telephone service to the study staff.

Intervention

Trial medication will be initiated on the randomisation day in a dosage of Enalapril 20 mg given in the morning or at bedtime and identical placebo tablets given in the morning and at bedtime. In patients not taking ACE-inhibitors before entrance into the study, a dose of Enalapril 10 mg in the

1
2
3
4
5
6
7
8 morning is given for 4 weeks to ensure tolerability of the drug. Thereafter, these patients are
9
10 randomised to Enalapril 20 mg given in the morning or at bedtime. Patients already in treatment
11
12 with ACE-inhibitors or ATII-blockers will discontinue this treatment when entering the study. All
13
14 other antihypertensive medication will be prescribed unchanged
15

16 17 18 **End-point measures**

19
20 The primary endpoint is to evaluate the effect of treatment with Enalapril 20 mg given at bedtime
21
22 compared with Enalapril 20 mg given in the morning on mean arterial blood pressure, systolic
23
24 blood pressure, diastolic blood pressure and percent dipping in MAP during night. The calculations
25
26 will be based on both 24-hour blood pressure readings in each treatment period.

27
28 Secondary endpoint is left ventricular volume and left ventricular mass measured by MSCT at the
29
30 end of each treatment period.
31

32 33 34 **Power calculation and statistics**

35
36 The crossover design makes it possible to compare the two treatment modalities within the same
37
38 person thereby minimising between-patient variation.

39
40 Setting power to 80%, a test level of 5% and a standard deviation of 5 mm Hg on blood pressure
41
42 measurements a sample size of 24 patients will be sufficient to detect a difference of 4 mmHg
43
44 between the two treatment modalities.

45
46 The results will be expressed as means and standard deviation when values are normally distributed
47
48 and as medians and interquartile range when the values are not normally distributed. Paired students
49
50 t-tests will be used when the values are skewed; otherwise Wilcoxon's tests for paired differences
51
52 are used. A two-tailed value of $p < 0.05$ will be considered statistically significant.
53
54
55
56
57
58
59
60

Ethics and dissemination

This investigator-initiated, randomised, double-blind trial has the potential to clarify whether it is possible to re-establish the diurnal variation of blood pressure in type 1 diabetic patients with a nondipping pattern of blood pressure during night. A positive outcome for the primary endpoint will also enable us to study the effect on end-organ changes as myocardial hypertrophy. Previous studies have suggested positive effects of bedtime dosing of antihypertensive medications in open, unblinded studies in type 2 diabetic patients, but double-blinded studies have not been performed and no studies at all have been carried out in type 1 diabetics. By studying the selected patients with CAN but without simultaneous diabetic nephropathy it is possible to evaluate the effect of nocturnal antihypertensive treatment in patients with autonomic CAN alone.

A positive outcome for the primary endpoint of the trial may pave the way for dosing antihypertensive medication at bedtime. However, larger trials with longer intervention periods are required to study the effects of such medication on hard clinical outcomes.

The potential side effects and risks will be minimised by close measurements of 24-hour blood pressure and monitoring of kidney function during the study.

The potential disadvantages, including expense of time, potential adverse events and discomfort related to blood pressure measurements and study visits are expected to be overshadowed by the knowledge and possible clinical importance that the trial outcome will produce.

The results of the study will be presented at national and international scientific meetings and publication will be submitted to peer-reviewed journals.

Table 1 Trial visits and examinations

Visit	1	2	3	4	5	6	7
Week	0	6	11	12	18	23	24
Informed consent	X						
Screening and randomisation	X						
Physical examination	X						
Blood samples (a)	X		X			X	
Dispense of trial medication	X		X				
Adverse event assessment		X	X	X	X	X	X
24-h blood pressure recording		X	X		X	X	
Heart-MSCT				X			X

- a) HbA1c, serum creatinine and NT-proBNP
- b) Cardiac Multiple Slice Computed Tomography (MSCT)

Contributorship statement:

TJ substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, drafted the article and has approved this version of the article. HH substantial contributed to conception and design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KK, UMM and LK substantial contributed to conception and design of the study, interpretation of data, revised the article and has approved this version of the article. KH contributed to design of the study, acquisition and interpretation of data, revised the article and has approved this version of the article. HN contributed to the design of the study, acquisition, analysis and interpretation of data, revised the article and has approved this version of the article. KT substantial contributed to conception and design of the study, acquisition and analysis of data, revised the article and has approved this version of the article. JH substantial contributed to conception and design of the study, analysis and interpretation of data, revised the article and has approved this version of the article.

Competing interests:

None

Funding

This study was supported by a grant from Arvid Nilssons Foundation.

References

- 1) Spallone V, Maiello MR, Cicconetti E, Pannone A, Barini A, Gambardella S, Menzinger G.. Factors determining the 24-h blood pressure profile in normotensive patients with type 1 and type 2 diabetes. *J Hum Hypertens* 2001; 15(4):239-246.
- 2) Taskiran M, Rasmussen V, Rasmussen B, Fritz-Hansen T, Larsson HB, Jensen GB, Hilsted J. Left ventricular dysfunction in normotensive type 1 diabetic patients: the impact of autonomic neuropathy. *Diabetic Med* 2004;21(6):524-530.
- 3) Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. *Circulation* 2007;115(3):387-397.
- 4) Cardoso CR, Leite NC, Freitas L, Dias SB, Muxfeld ES, Salles GF. Pattern of 24-hour ambulatory blood pressure monitoring in type 2 diabetic patients with cardiovascular dysautonomy. *Hypertens Res* 2008; 31(5):865-872.
- 5) Hornung RS, Mahler RF, Raftery EB. Ambulatory blood pressure and heart rate in diabetic patients: an assessment of autonomic function. *Diabetic Med* 1989;6(7):579-585.
- 6) Monteagudo PT, Nobrega JC, Cezarini PR, Ferreira SR, Kohlmann O, Ribeiro AB, Zanella M-T. Altered blood pressure profile, autonomic neuropathy and nephropathy in insulin-dependent diabetic patients. *Eur J Endocrinol* 1996;135(6):683-688.
- 7) Spallone V, Bernardi L, Ricordi L, Solda P, Maiello MR, Calciati A, Gombardella S, Fratino P, Menzinger G. Relationship between the circadian rhythms of blood pressure and sympatovagal balance in diabetic autonomic neuropathy. *Diabetes* 1993;42(12):1745-1752.
- 8) Spallone V, Maiello MR, Morganti R, Mandica S, Frajes G. Usefulness of ambulatory blood pressure monitoring in predicting the presence of autonomic neuropathy in type 1 diabetic patients. *J Hum Hypertens* 2007;21(5):381-386.

- 1
2
3
4
5
6
7
8 9) Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, Guerrieri M,
9
10 Gatteschi C, Zampi I, Santucci A, Santucci C, Reboldi G. Ambulatory blood pressure. An
11
12 independent predictor of prognosis in essential hypertension. *Hypertension* 1994;24(6):793-
13
14 801.
- 15
16 10) Sturrock ND, George E, Pound N, Stevenson J, Peck GM, Sowter H. Non-dipping circadian
17
18 blood pressure and renal impairment are associated with increased mortality in diabetes
19
20 mellitus. *Diabetic Med* 2000;17(5):360364.
- 21
22 11) Okhubo T, Hozawa A, Yamaguchi J, Kikuya M, Ohmori K, Michimata M, Matsubora M,
23
24 Hashimoto J, Hoshi H, Araki T, Tsuji I, Satoh H, Hisamachi S, Imai Y. Prognostic
25
26 significance of the nocturnal decline in blood pressure in individuals with and without high
27
28 24-h blood pressure: The Ohasama Study. *J Hypertens* 2002;20(11):2183-2189.
- 29
30 12) Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure
31
32 variation and all-cause mortality. *Am J Hyertens* 2008;21(1):92-97.
- 33
34 13) Dolan E, Stanton A, Thijs L, Hinedi K, Atkins N, McClory S, Den Hand E, McCormack P,
35
36 Staessen JA, O'Brien E. Superiority of ambulatory over clinic blood pressure measurements
37
38 in predicting mortality: The Dublin Outcome Study. *Hypertension* 2005;46(1):156-161.
- 39
40 14) Boggia J, Li Y, Thijs L, Hansen TW, Kikuya M, Bjorklun-Bodegard K, Richart T, Okkubo
41
42 T, Kuznetsova T, Torp-Pedersn C, Lind L, Ibsen H, Imai Y, Wang J, Sandoya E, O'Brien E,
43
44 Stassen JA. Prognostic accuracy of day versus night ambulatory blood pressure: A cohort
45
46 study. *Lancet* 2007;370(9594)1219-1229.
- 47
48 15) Mogensen UM, Jensen T, Køber L, Kelbæk H, Mathiesen AS, Dixen U, Rossing P, Hilsted
49
50 J, Kofoed KF. Cardiovascular autonomic neuropathy and subclinical cardiovascular disease
51
52 in normoalbuminuric type 1 diabetic patients. *Diabetes* 2012;61:1822-1830.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8 16) Hermida RC, Ayala DE, Fernandez JR, Calvo C. Chronotherapy improves blood pressure
9 control and reverts the nondipper pattern in patients with resistant hypertension.
10 Hypertension 2008;51(1):69-76.
11
12
13 17) Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular
14 autonomic neuropathy and mortality in individuals with diabetes: a metaanalysis. Diabetes
15 Care 2003;26(6):1895-1901.
16
17
18 18) Kontopoulos AG, Athyros VG, Didangelos TP, Papageorgiou AA, Avradimis MJ, Mayroui
19 MC, Karamitsos DT. Effect of chronic quinapril administration on heart rate variability in
20 patients with diabetic autonomic neuropathy. Diabetes Care 1997;20(3):355-361
21
22
23 19) Cabezas-Cerrato J, Hermida RC, Cabezas-Agricola JM, Auala DE. Cardiac autonomic
24 neuropathy, estimated cardiovascular risk, and circadian blood pressure pattern in diabetes
25 mellitus. Chronobiol Int 2009;26(5):942-957.
26
27
28 20) Roy TM, Peterson, HR, Snider HL, Cyrus J, Broadstone VL, Fell RD, Rothchild AH,
29 Samols E, Pfeifer MA. Autonomic influence on cardiovascular performance in diabetic
30 subjects. Am J Med 1989;87:383-388.
31
32
33 21) Airaksinen KEJ. Silent coronary artery disease in diabetes: a feature of autonomic
34 neuropathy or accelerated atherosclerosis? Diabetologia 2001;44:259-266.
35
36
37 22) Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes
38 Care 2003;26:1553-1579.
39
40
41 23) The effect of intensive diabetes therapy on measures of autonomic nervous system function
42 in the Diabetes Control and Complications Trial (DCCT). Diabetologia 1998;41:416-423.
43
44
45 24) Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE,
46 Sosenko JM, Ziegler D. Diabetic neuropathies: a statement by the American Diabetes
47 Association. Diabetes Care 2005;28:956-962.
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8 25) Knudsen ST, Ebbenhøj E, Poulsen PL, Hansen KW. Targeting nocturnal hypertension in type
9
10 2 diabetes: bedtime dosing of once-daily antihypertensive drugs reduces night-time BP and
11
12 24-h BP. *Diabetologia* 2013;56(Suppl 1);1208:486.
13
14 26) Hermida RC, Ayala DE, Mojon A, Fernandez JR. Influence of time of day of blood
15
16 pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2
17
18 diabetes. *Diabetes Care* 2011;34:1270-1276.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Correction

Hjortkær H, Jensen T, Kofoed K, *et al.* Nocturnal antihypertensive treatment in patients with type 1 diabetes with autonomic neuropathy and non-dipping of blood pressure during night time: protocol for a randomised, placebo-controlled, double-blind, two-way crossover study. *BMJ Open* 2014;4:e006142. The name of the first author of this paper was spelled incorrectly. This author's correct name is Henrik Øder Hjortkær.

BMJ Open 2015;5:e006142corr1. doi:10.1136/bmjopen-2014-006142corr1



CrossMark